Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

ARWR· Manufacturing· Fiscal year ends in September

CEO pay in FY2025Stock +78.1% in FY2025

Christopher Anzalone is the CEO of Arrowhead Pharmaceuticals and was paid $9.0M in FY2025 (Sep), down 27%.

Pay$100 in the stock at the end of FY20 → $80
CEO pay is from each Arrowhead Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Christopher AnzaloneFY2025
  2. 2Patrick O’BrienFY2025
  3. 3James HamiltonFY2025
  4. 4Kenneth MyszkowskiFY2025
  5. 5Tracie OliverFY2025
  6. 6Daniel ApelNot disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Arrowhead Pharmaceuticals paid its 5 named executives $17.7M in total in FY2025 (Sep). CEO Christopher Anzalone was paid $9.0M of that.

Name
Christopher AnzalonePresident and Chief Executive Officer
Patrick O’BrienChief Operating Officer
James HamiltonChief Medical Officer
Kenneth MyszkowskiFormer Chief Financial Officer
Tracie OliverFormer Chief Commercial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Sep) proxy of Arrowhead Pharmaceuticals names 20 peer companies for pay. Pay versus performance data of Arrowhead Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Douglass GivenChair · 13 yr on the boardIndependentCompensation, Nomination (Chair), Science—Paid as an executive
  • Mauro Ferrari, PhDDirector · 13 yr on the boardIndependentAudit, Nomination—Paid as an executive
  • Michael S. PerryDirector · 12 yr on the boardIndependentCompensation, Nomination—Paid as an executive

The board of the latest proxy (FY2023).

Activity

  1. Pay
    Arrowhead Pharmaceuticals Former Chief Commercial Officer pay fell 99% to $43.2K. The stock rose 78% in FY2025 (Sep).
    DEF 14A
  2. Pay
    Arrowhead Pharmaceuticals COO pay fell 23% to $3.0M. The stock rose 78% in FY2025 (Sep).
    DEF 14A
  3. Pay
    Arrowhead Pharmaceuticals Former CFO pay fell 24% to $2.7M. The stock rose 78% in FY2025 (Sep).
    DEF 14A
  4. Pay
    Arrowhead Pharmaceuticals Chief Medical Officer pay fell 15% to $3.0M. The stock rose 78% in FY2025 (Sep).
    DEF 14A
  5. Pay
    Arrowhead Pharmaceuticals CEO pay fell 27% to $9.0M. The stock rose 78% in FY2025 (Sep).
    DEF 14A
  6. Pay
    Arrowhead Pharmaceuticals Former Chief Commercial Officer pay rose 252% to $3.1M. The stock fell 28% in FY2024 (Sep).
    DEF 14A
  7. Pay
    Arrowhead Pharmaceuticals Former Chief Commercial Officer pay fell 68% to $873.8K. The stock fell 19% in FY2023 (Sep).
    DEF 14A
  8. Pay
    Arrowhead Pharmaceuticals COO pay rose 19% to $3.9M. The stock fell 28% in FY2024 (Sep).
    DEF 14A
  9. Pay
    Arrowhead Pharmaceuticals COO pay fell 11% to $4.7M. The stock fell 47% in FY2022 (Sep).
    DEF 14A
  10. Pay
    Arrowhead Pharmaceuticals Former CFO pay rose 13% to $3.5M. The stock fell 28% in FY2024 (Sep).
    DEF 14A
  11. Pay
    Arrowhead Pharmaceuticals Former CFO pay fell 11% to $4.7M. The stock fell 47% in FY2022 (Sep).
    DEF 14A
  12. Pay
    Arrowhead Pharmaceuticals Former Chief Medical Officer pay rose 12% to $3.5M. The stock fell 28% in FY2024 (Sep).
    DEF 14A
  13. Pay
    Arrowhead Pharmaceuticals Chief Medical Officer pay rose 14% to $3.5M. The stock fell 28% in FY2024 (Sep).
    DEF 14A
  14. Pay
    Arrowhead Pharmaceuticals CEO pay rose 25% to $12.4M. The stock fell 28% in FY2024 (Sep).
    DEF 14A
  15. Pay
    Arrowhead Pharmaceuticals CEO pay fell 51% to $12.0M. The stock fell 47% in FY2022 (Sep).
    DEF 14A
  16. Pay
    Arrowhead Pharmaceuticals COO pay fell 30% to $3.3M. The stock fell 19% in FY2023 (Sep).
    DEF 14A
  17. Pay
    Arrowhead Pharmaceuticals Former CFO pay fell 34% to $3.1M. The stock fell 19% in FY2023 (Sep).
    DEF 14A
  18. Pay
    Arrowhead Pharmaceuticals Former Chief Medical Officer pay rose 339% to $3.1M. The stock fell 19% in FY2023 (Sep).
    DEF 14A
  19. Pay
    Arrowhead Pharmaceuticals Chief Medical Officer pay fell 30% to $3.0M. The stock fell 19% in FY2023 (Sep).
    DEF 14A
  20. Pay
    Arrowhead Pharmaceuticals CEO pay fell 18% to $9.9M. The stock fell 19% in FY2023 (Sep).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AJan 27, 2026FY2025
Annual report10-KNov 25, 2025FY2025
Proxy statementDEF 14AJan 29, 2025FY2024
Annual report10-KNov 26, 2024FY2024
Proxy statementDEF 14AJan 26, 2024FY2023
Annual report10-KNov 29, 2023FY2023
For the press:Download CSVDownload PNGHow to use our data